Physician profile
Joan E Quinn
NPI 1104938786
$10,920.18
in general payments reported to CMS, 2019-2025
59 companies · $2,004 in 2025
The $2,004 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,782 · 2020: $911 · 2021: $1,518 · 2022: $1,738 · 2023: $1,845 · 2024: $1,122 · 2025: $2,004.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,972.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,971.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,227.18 | 2019-2025 | |
| Amgen INC. | $1,350.37 | 2019-2025 | Evenity, Repatha, Prolia |
| Novo Nordisk INC | $1,198.46 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $1,110.84 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $908.19 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $429.16 | 2019-2025 | |
| Axsome Therapeutics, INC. | $366.57 | 2025 | Auvelity, Symbravo |
| Otsuka America Pharmaceutical, INC. | $303.32 | 2023-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $285.44 | 2019-2024 | Invega Sustenna, Xarelto |
| Takeda Pharmaceuticals U.S.A., INC. | $241.58 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $203.79 | 2020-2025 | Vaxneuvance, Gardasil 9, Rotateq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $184.99 | 2021-2025 | Xifaxan |
| Astellas Pharma US INC | $153.76 | 2023-2025 | Veozah, Myrbetriq |
| Currax Pharmaceuticals LLC | $152.89 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $147.98 | 2022 |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joan Quinn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.